Advanced Clinical A.I CyberSecurity Scoring
30/12/2025
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Advanced Clinical in 2026.
No incidents recorded for Advanced Clinical in 2026.
No incidents recorded for Advanced Clinical in 2026.
CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra
Avantor® is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 14,500 strong, our associates are passionate about our mission to set science in motion to create a better world. We share enthusiasm for innovation, excellence, and achievement. Whether we are collaborating with our customers to advance science or solve multifaceted problems, we help them reach their goals more efficiently and effectively. Visit our website to learn more about Avantor.
Fortrea (Nasdaq: FTRE) is a leading global clinical research organization (CRO) dedicated to providing innovative clinical development solutions to the life sciences industry. With over 30 years of clinical research experience, Fortrea has evolved from Covance and Labcorp into a pureplay CRO built for biotech, biopharma, medical device and diagnostic innovators. Fortrea collaborates with both emerging and established companies to deliver agile, fit-for-purpose full service (FSO), functional service (FSP) and hybrid solutions. Fortrea provides comprehensive Phase I-IV clinical trial management, clinical pharmacology, and consulting services, backed by deep experience in more than 20 therapeutic areas. Operating in approximately 100 countries, our diverse and talented team brings scientific rigor, operational excellence, and a strong investigator site network to every trial. By combining the best of our legacy experience with forward-thinking innovation, Fortrea brings predictability to clinical trial execution and helps transform aspirations into outcomes. Together, exceptional is possible. Learn more at Fortrea.com
At Charles River, we are guided by our strong purpose—to create healthier lives—which centers around the patients who rely on the therapeutics we help to develop, the animals in our care, to our planet, and to the passionate and skilled people who are at the heart of our organization and make it all possible. #DrugDiscovery #Biotech #Biotechnology #Pharmaceuticals #CRL
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
NIH is the only agency of its kind. We impact the health of the country and the world through unique and innovative medical research. Did you know that NIH is the largest public funder of biomedical research in the world, investing more than $32 billion a year to enhance life, and reduce illness and disability? NIH funded research has led to breakthroughs and new treatments, helping people live longer, healthier lives, and building the research foundation that drives discovery. Whether you are graduating with a bachelor's degree, working on your doctoral degree, entering the workforce for the first time, or changing careers, NIH offers a place for you to start and plenty of room to grow your career. When you join us, you’re not just advancing your career — you’re driving the health of our country forward. Official LinkedIn Account of the NIH. Privacy policy: http://go.usa.gov/x9svN Comment policy: https://bit.ly/3G6xq94 Engagement ≠ endorsement
Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation
About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or [email protected]. Community Guidelines: 1. We want to foster positive conversation around the issues we are passionate about. To that end, we remove profanity, content that contains threatening language, content that is aimed at private individuals, personal information, and repeated unwanted messages. 2. Don’t mention any medicines by name — ours or anyone else’s. Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments. 3. This isn’t the place to report or discuss side effects. This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch. 4. Don’t pitch your product or service. Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.
Latest updates, reports, and threat intel affecting the global network.
The Department of Health and Human Services (HHS) is asking industry experts to weigh in on how federal regulation, reimbursement,...
Global Healthcare Cybersecurity Market Size, Share, Trends & Growth Forecast Report By Offering (Solutions, Services), Threat Type (Malware,...
The Advanced Medical Technology Association (AdvaMed) updated its Code of Ethics effective November 1, 2025, primarily to add a new section...
South Texas College's Bachelor of Applied Technology Computer Information Technology (BAT-CIT) through its upcoming Cybersecurity Clinic now...
Secure by design. We define the appropriate risk-based design inputs early in the development process. Icon of slider options. Security controls.
The healthcare cyber security market size is calculated at USD 24.39 billion in 2025 and is expected to reach around USD 112.6 billion by...
PRNewswire/ -- Cybersecurity and compliance firm 360 Advanced is proud to announce the successful acquisition of Security Compliance...
Many smart medical devices in health care today are not designed with security in mind, exposing sensitive data to risk. Read more
The South Texas College Cybersecurity program recently secured a $467000 Advanced Technological Education (ATE) grant from the National...
Improper Handling of Highly Compressed Data (Data Amplification) vulnerability in elixir-grpc grpc (GRPC.Compressor.Gzip, GRPC.Message modules) allows a denial of service via a gzip decompression bomb. This vulnerability is associated with program files lib/grpc/compressor/gzip.ex, lib/grpc/message.ex and program routines 'Elixir.GRPC.Compressor.Gzip':decompress/1, 'Elixir.GRPC.Message':from_data/2. 'Elixir.GRPC.Compressor.Gzip':decompress/1 calls :zlib.gunzip/1 directly on attacker-controlled bytes with no decompressed-size limit, ratio check, or incremental decoding. Because this module is the registered gzip GRPC.Compressor implementation, it is invoked automatically whenever an incoming gRPC frame carries the grpc-encoding: gzip header. :zlib.gunzip/1 allocates the entire decompressed result as a single binary, so a small highly compressible payload (for example a few kilobytes of zeros, which gzip compresses at roughly 1000:1) expands to multiple gigabytes inside a single call. The max_receive_message_length limit is enforced only against the already-decompressed message, so it provides no protection. An unauthenticated remote peer can send a single crafted frame to exhaust the BEAM node's heap and trigger an out-of-memory kill. This issue affects grpc: from 0.4.0 before 1.0.0.
Allocation of Resources Without Limits or Throttling vulnerability in elixir-grpc grpc allows unauthenticated attackers to exhaust the BEAM's memory and crash the server by streaming a large or slow-trickle unary request body. 'Elixir.GRPC.Server.Adapters.Cowboy.Handler':read_full_body/3 (lib/grpc/server/adapters/cowboy/handler.ex) accumulates every received chunk into a single growing binary with no size cap. Additionally, when the client omits the grpc-timeout header, the per-chunk read timeout resolves to :infinity, allowing a slow-trickle client to keep the connection alive indefinitely while memory grows. A single connection is sufficient to exhaust server memory and crash the node. This issue affects grpc from 0.3.1 before 1.0.0.
Deserialization of Untrusted Data and Allocation of Resources Without Limits or Throttling vulnerabilities in elixir-grpc grpc allow unauthenticated attackers to crash the BEAM node via atom table exhaustion and, when a decoded term flows into a call site that invokes it, achieve remote code execution on the server. 'Elixir.GRPC.Codec.Erlpack':decode/2 (lib/grpc/codec/erlpack.ex) calls :erlang.binary_to_term/1 on the raw gRPC message body without the :safe option, no size bound, and no type guard. Any unauthenticated peer that sends a request with Content-Type: application/grpc+erlpack can send a crafted payload that mints arbitrary new atoms (which are never garbage-collected, exhausting the bounded atom table and crashing the VM) or that encodes a fun term which, if applied anywhere downstream, executes attacker-controlled code inside the server process. This issue affects grpc from 0.4.0 before 1.0.0.
The browserstack-cypress-cli is BrowserStack's CLI which allows users to run Cypress tests on BrowserStack. Versions prior to 1.36.4 are vulnerable to OS command injection via the cypress_config_file configuration parameter. In readCypressConfigUtil.js, the loadJsFile() function constructs a shell command by interpolating the user-controlled cypress_config_filepath value into a template literal, then executes it via child_process.execSync(). Shell metacharacters in the config path (specifically " and ;) allow breaking out of the quoted argument and injecting arbitrary commands. This issue has been fixed in version 1.36.6.
Authorization Bypass Through User-Controlled Key vulnerability in elixir-grpc grpc allows authenticated attackers to access or modify resources belonging to other users by smuggling a conflicting value for any path-bound field via the query string or request body. In 'Elixir.GRPC.Server.Transcode':map_request/5 (lib/grpc/server/transcode.ex), all three clauses use Map.merge/2 with path bindings as the first argument, giving them the lowest merge precedence. A request such as GET /users/me/profile?user_id=victim (or a POST with {"user_id": "victim"} when body: "*") yields a decoded protobuf struct where the path-bound field carries the attacker-supplied value rather than the router-extracted value. Any handler that uses the path-bound field for authorization, multi-tenancy scoping, or ownership checks is silently bypassed. This issue affects grpc from 0.8.0 before 1.0.0.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.